The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
Many studies have reported that African-American men have the highest incidence and mortality rates for prostate cancer in the United States. A retrospective analysis of 607 patients treated with definitive radiation therapy was performed at the University of California San Francisco and its affiliated hospitals between 1987 and 1995. The patient population analyzed included African-American, Caucasian, and Asian men with AJCC T1-T3 disease. Race, Gleason score, pretreatment prostate-specific antigen levels, stage, and treatment delivery were all evaluated. The percent free from PSA failure at 48 months for African-American, Caucasian, and Asian men were 53%, 59%, and 53%, respectively. There was no difference among the three races or for any of the pairwise comparisons. Gleason score and stage of disease were each independent predictors of outcome, but race was not associated with remaining free from PSA failure. These results are similar to those recently reported in the literature from centers of excellence across the United States.